Boehringer Ingelheim Pharmaceuticals, Inc.

Société pharmaceutique10 produits suivis

produits suivis

271 920

total des notifications

rappels enregistrés

61,6%

graves au total

Produits

affichage de 10 sur 10

Produit	Approuvé	Notifications ↓	Signal principal	Rappels
tiotropium bromide —	2004	150 254	voie d'administration du médicament incorrecte	0
empagliflozin —	2014	69 331	Acidocétose diabétique euglycémique	7
linagliptin —	2011	20 890	Cécité	2
tiotropium bromide inhalation spray —	—	10 745	trouble du sommeil dû à une condition médicale générale	0
afatinib —	2013	6 549	Mutation du gène EGFR	0
tiotropium bromide and olodaterol —	—	4 837	Bronchopneumopathie chronique obstructive	0
empagliflozin, metformin hydrochloride —	—	3 303	Acidocétose diabétique euglycémique	0
empagliflozin and metformin hydrochloride —	—	2 719	Acidocétose diabétique euglycémique	4
empagliflozin and linagliptin —	—	1 913	Acidocétose diabétique euglycémique	1
tipranavir —	2005	1 379	Extrophie cloacale	0

Historique des rappels · 16 enregistrés

Date	Classe	Motif	Fabricant
9 mars 2023	II	Labeling: Label Mix-up	Boehringer Ingelheim Pharmaceuticals, Inc.
26 janv. 2022	II	CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.	CARDINAL HEALTHCARE
15 mars 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mars 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mars 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mars 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
15 mars 2021	II	CGMP Deviations: Intermittent exposure to temperature excursion during storage.	Cardinal Health Inc.
5 oct. 2020	II	An extraneous peak was observed for dissolution testing.	Boehringer Ingelheim Pharmaceuticals, Inc.
5 oct. 2020	II	An extraneous peak was observed for dissolution testing.	Boehringer Ingelheim Pharmaceuticals, Inc.
5 oct. 2020	II	An extraneous peak was observed for dissolution testing.	Boehringer Ingelheim Pharmaceuticals, Inc.
7 mars 2019	III	Failed Tablet/Capsule Specifications: identification of low weight tablets during routine stability testing.	Boehringer Ingelheim Pharmaceuticals, Inc.
22 oct. 2018	II	Failed Dissolution Specifications: OOS resultsduring routine stability testing	Boehringer Ingelheim Pharmaceuticals, Inc.
4 sept. 2018	II	Cross Contamination With Other Products:	Boehringer Ingelheim Pharmaceuticals, Inc.
22 sept. 2017	III	Labeling: Incorrect or missing package insert. One lot of Mobic Tablets is packaged with an incorrect insert.	Boehringer Ingelheim Pharmaceuticals, Inc.
6 oct. 2016	II	Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count bottle of 75 mg Dipyridamole.	Boehringer Ingelheim Pharmaceuticals, Inc.
6 oct. 2016	II	Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count bottle of 75 mg Dipyridamole.	Boehringer Ingelheim Pharmaceuticals, Inc.

Classe I = probabilité raisonnable de préjudice grave · Classe II = temporaire ou réversible · Classe III = peu susceptible de causer un préjudice.

Statut d'enregistrement

Certains produits de Boehringer Ingelheim Pharmaceuticals, Inc. ne sont pas enregistrés auprès de la FDA pour un usage humain. Pour les substances non enregistrées (peptides, SARMs sans enregistrement humain), aucun fournisseur légitime à usage humain n'existe. L'absence de filière d'approvisionnement est l'information de sécurité.